TITLE:
Study Evaluating Venlafaxine ER in Patients With Panic Disorder

CONDITION:
Panic Disorder

INTERVENTION:
Venlafaxine ER

SUMMARY:

      The primary objective is to determine the efficacy, safety, and tolerability of venlafaxine
      extended release (ER) capsules in the treatment of outpatients with panic disorder (PD) in
      comparison to those of placebo.
    

DETAILED DESCRIPTION:
NONE

ELIGIBILITY:
Gender: All
Age: 18 Years to N/A
Criteria:

        Inclusion Criteria:

          -  Meet DSM-IV criteria for PD (with or without agoraphobia) for at least 3 months
             before study day 1

          -  Have sufficient symptoms to require anxiolytic drug therapy

          -  Have a score 4 on the Clinical Global Impressions Scale (CGI) severity of illness
             item at screening and baseline

        Exclusion Criteria:

          -  Known hypersensitivity to venlafaxine (IR or ER), related compounds, or paroxetine

          -  History or presence of any clinically important hepatic, renal, or other medical
             disease that might compromise the study or be detrimental to the patient (eg,
             clinically important cardiac arrhythmia, unstable diabetes, carcinoma [except basal
             cell epithelioma], uncontrolled hypertension)

          -  Clinically important abnormality on screening physical examination, vital signs,
             electrocardiogram (ECG), laboratory tests or urine drug screen
      
